Science Explorer Back to mapMap
Discussion
Company · Gumi · South Korea

Jeuk (South Korea)

jeuk21.com/index_eng.phpROR OpenAlex
Research works
20
▲ 6% vs 2018-21
Citations
582
28.6 per fractional work
Top-10% rate
12.5%
all institutions 10.0%
Open access
56%
world 40%
International
30%
world 18%
Jeuk (South Korea)

Not ranked overall: Jeuk (South Korea) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Jeuk (South Korea) work in?

In all years, 52% of research at Jeuk (South Korea) is in Health Sciences, 42% in Life Sciences. Its largest fields are Medicine (52%), Biochemistry, Genetics and Molecular Biology (29%), Immunology and Microbiology (11%). It does 1.9× the world's share of Life Sciences.

Health Sciences: 11 fractional works · 52.5% of its workMedicine: 11 fractional works · 52.1% of its workOncology: 5 fractional works · 24.3% of its workPulmonary and Respiratory Medicine: 3 fractional works · 17.0% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 4.0% of its workOtorhinolaryngology: 0 fractional works · 1.9% of its workSurgery: 0 fractional works · 1.3% of its workGenetics: 0 fractional works · 0.8% of its workPsychiatry and Mental health: 0 fractional works · 0.6% of its workHepatology: 0 fractional works · 0.5% of its workImmunology and Allergy: 0 fractional works · 0.4% of its workPathology and Forensic Medicine: 0 fractional works · 0.4% of its workRheumatology: 0 fractional works · 0.4% of its workPharmacology: 0 fractional works · 0.3% of its workHealth Professions: 0 fractional works · 0.3% of its workRadiological and Ultrasound Technology: 0 fractional works · 0.3% of its workLife Sciences: 9 fractional works · 42.1% of its workBiochemistry, Genetics and Molecular Biology: 6 fractional works · 29.1% of its workMolecular Biology: 3 fractional works · 12.8% of its workCancer Research: 2 fractional works · 9.6% of its workBiotechnology: 1 fractional works · 4.8% of its workBiochemistry: 0 fractional works · 0.7% of its workCell Biology: 0 fractional works · 0.7% of its workGenetics: 0 fractional works · 0.4% of its workImmunology and Microbiology: 2 fractional works · 11.5% of its workImmunology: 2 fractional works · 11.5% of its workAgricultural and Biological Sciences: 0 fractional works · 1.2% of its workPlant Science: 0 fractional works · 1.2% of its workNeuroscience: 0 fractional works · 0.3% of its workBiological Psychiatry: 0 fractional works · 0.3% of its workPhysical Sciences: 1 fractional works · 5.4% of its workEngineering: 1 fractional works · 4.6% of its workBiomedical Engineering: 1 fractional works · 3.4% of its workCivil and Structural Engineering: 0 fractional works · 0.8% of its workBuilding and Construction: 0 fractional works · 0.4% of its workEnvironmental Science: 0 fractional works · 0.8% of its workHealth, Toxicology and Mutagenesis: 0 fractional works · 0.8% of its workALL ITS WORKJeuk (SouthKorea)20fractional works, all years
Life Sciences42%Physical Sciences5%Health Sciences52%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 8 fields, with their numbers
    1. Medicine1152.1%
    2. Health Professions00.3%
    1. Biochemistry, Genetics and Molecular Biology629.1%
    2. Immunology and Microbiology211.5%
    3. Agricultural and Biological Sciences01.2%
    4. Neuroscience00.3%
    1. Engineering14.6%
    2. Environmental Science00.8%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 5.13× its world share, 2 worksBiochemistry, Geneti…Immunology and Microbiology: 10.86× its world share, 1 worksImmunology and Micro…Neuroscience: 0.41× its world share, 0 worksNeuroscienceEngineering: 0.70× its world share, 1 worksEngineeringEnvironmental Science: 0.40× its world share, 0 worksEnvironmental ScienceMedicine: 2.53× its world share, 4 worksMedicine1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 10.9×. Every wedge is a field page.

All 6 fields, with their numbers
  1. Immunology and Microbiology10.86×1 works
  2. Biochemistry, Genetics and Molecular Biology5.13×2 works
  3. Medicine2.53×4 works
  4. Engineering0.70×1 works
  5. Neuroscience0.41×0 works
  6. Environmental Science0.40×0 works

What are the most cited papers from Jeuk (South Korea)?

The most cited paper from Jeuk (South Korea) is "Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer" (Chun‐Gon Kim, Kyoung‐Ho Kim, Kyoung‐Ho Pyo et al., 2019), with 305 citations. Next come "Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC" (300) and "Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer" (293).

Most cited papers
#PaperReleasedCitations
1 Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer Chun‐Gon Kim, Kyoung‐Ho Kim, Kyoung‐Ho Pyo et al. · Annals of Oncology Open access 6 Apr 2019 305
2 Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC Jiyeon Yun, Soo‐Hwan Lee, Seok-Young Kim et al. · Cancer Discovery Open access 15 May 2020 300
3 Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer Jae-Won Cho, Min Hee Hong, Sang‐Jun Ha et al. · Experimental & Molecular Medicine Open access Sep 2020 293
4 PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients Hye Ryun Kim, Sang‐Jun Ha, Min Hee Hong et al. · Scientific Reports Open access 14 Nov 2016 262
5 YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer Jiyeon Yun, Min Hee Hong, Seok‐Young Kim et al. · Clinical Cancer Research Open access 22 Jan 2019 133
All 48 most cited papers, with filters and sorting

Which keywords describe research at Jeuk (South Korea)?

By fractional works in all years, weighted toward what it does more of than the world: Targeted Therapy, Tumor Microenvironment, Clinical Trials, Cancer, Immunotherapy, Chemotherapy, ALK Inhibitors and EGFR Mutations.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 22 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 22 words, with their numbers
  1. Targeted Therapy4▲ 99×4 topics
  2. Tumor Microenvironment4▲ 51×6 topics
  3. Clinical Trials3▲ 23×2 topics
  4. Cancer3▲ 10×13 topics
  5. Chemotherapy3▲ 19×9 topics
  6. Immunotherapy3▲ 21×7 topics
  7. ALK Inhibitors2▲ 216×1 topic
  8. EGFR Mutations2▲ 216×1 topic
  9. Immune Checkpoint Blockade2▲ 150×1 topic
  10. PD-1 and PD-L12▲ 150×1 topic
  11. Inflammation2▲ 3.3×5 topics
  12. Metabolism2▲ 12×4 topics
  13. Genomic Instability1▲ 52×2 topics
  14. Cancer Genomics1▲ 116×1 topic
  15. Cancer Immunotherapy1▲ 45×3 topics
  16. Mutational Signatures1▲ 116×1 topic
  17. Tumor Regression1▲ 73×2 topics
  18. Gene Expression1▲ 9.8×6 topics
  19. Immunity1▲ 18×2 topics
  20. Gene Therapy1▲ 21×3 topics
  21. Radiotherapy1▲ 14×5 topics
  22. Tumor Targeting1▲ 42×2 topics

Which research topics does Jeuk (South Korea) publish most on?

By volume in 2022-now: Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics and Immune cells in cancer.

Lung Cancer Treatments and Mutations: 1 fractional worksCancer Immunotherapy and Biomarkers: 1 fractional worksCancer Genomics and Diag…1Cancer Genomics and Diagnostics: 1 fractional worksImmune cells in cancer1Immune cells in cancer: 1 fractional worksFerroptosis and cancer p…0Ferroptosis and cancer prognosis: 0 fractional worksCancer Cells and Metasta…0Cancer Cells and Metastasis: 0 fractional works3D Printing in Biomedica…03D Printing in Biomedical Research: 0 fractional worksInnovative Microfluidic and Catalytic Techniques Innovation: 0 fractional worksSingle-cell and spatial transcriptomics: 0 fractional worksRadiomics and Machine Learning in Medical Imaging: 0 fractional works
Pulmonary and Respiratory MedicineOncologyCancer ResearchImmunology3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 1 works
  2. 2 Cancer Immunotherapy and Biomarkers Oncology 1 works
  3. 3 Cancer Genomics and Diagnostics Cancer Research 1 works
  4. 4 Immune cells in cancer Immunology 1 works
  5. 5 Ferroptosis and cancer prognosis Pulmonary and Respiratory Medicine 0 works
  6. 6 Cancer Cells and Metastasis Oncology 0 works
  7. 7 3D Printing in Biomedical Research Biomedical Engineering 0 works
  8. 8 Innovative Microfluidic and Catalytic Techniques Innovation Biomedical Engineering 0 works
  9. 9 Single-cell and spatial transcriptomics Molecular Biology 0 works
  10. 10 Radiomics and Machine Learning in Medical Imaging Radiology, Nuclear Medicine and Imaging 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available56.1%not open43.9%

World: 40% of research is openly available.

with international co-authors29.9%domestic only70.1%

World: 18% is written across borders.

How has Jeuk (South Korea)'s research output changed?

Output in 2022-2025 was 6% higher than in 2018-2021.

still counting201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Jeuk (South Korea) as a percentage of every work published that year, 0.000072% in 2024.

still counting0.000050%0.00010%Jeuk (South Korea)0.000024% in 20252020

Fractional works of Jeuk (South Korea) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Gumi

All research institutions in Gumi

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Jeuk (South Korea). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.